How India Exports Mitomycin to the World

In the United States, mitomycin is approved for various oncological indications. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for mitomycin, indicating a competitive generic market. Notably, on June 12, 2025, the FDA approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.

As of March 2026, there are no active FDA import alerts specifically targeting mitomycin from Indian manufacturers. This absence suggests compliance with FDA regulations among Indian exporters. Given that 213 Indian exporters are actively involved in mitomycin exports, maintaining stringent quality standards is imperative to ensure continued market access.

In the European Union, the European Medicines Agency (EMA) oversees the approval and regulation of medicinal products, including mitomycin. Mitomycin is authorized for use in various cancer treatments across EU member states. Similarly, in the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) regulates mitomycin, ensuring its safety and efficacy.

Manufacturers exporting mitomycin to the EU and UK must comply with Good Manufacturing Practice (GMP) standards as outlined by the EMA and MHRA. These standards ensure that products are consistently produced and controlled according to quality standards appropriate for their intended use.

Mitomycin is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its significance in global health. The 24th edition of the list, published on September 5, 2025, continues to feature mitomycin as an essential medicine. (who.int)

Regarding pharmacopoeial standards, mitomycin is listed in major compendia, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Compliance with these standards ensures the quality, safety, and efficacy of mitomycin across different markets.

In India, mitomycin is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, mitomycin is not listed under the Drug Price Control Order (DPCO), allowing manufacturers to set prices based on market dynamics.

For export purposes, Indian manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring that the export complies with national regulations and does not adversely affect domestic availability.

Mitomycin's primary patents have expired, leading to the availability of generic versions in various markets. This expiration has intensified competition among manufacturers, including Indian exporters, who have capitalized on the opportunity to supply generic mitomycin globally.

In June 2025, the FDA approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.

In September 2025, the WHO published the 24th edition of its Model List of Essential Medicines, reaffirming mitomycin's status as an essential medicine. (who.int)

In January 2026, the FDA issued Import Alert 89-08, concerning devices without approved PMAs or IDEs. While not directly related to mitomycin, this alert underscores the FDA's ongoing vigilance in regulating medical products.

In February 2026, the USPTO updated its Patent Center, enhancing transparency and accessibility for stakeholders monitoring patent statuses, including those related to pharmaceuticals like mitomycin.

In March 2026, the WHO launched a digital version of its Model List of Essential Medicines, facilitating easier access and reference for healthcare professionals and regulators worldwide. (who.int)

These developments reflect the dynamic regulatory and market environment surrounding mitomycin, emphasizing the importance of continuous monitoring and compliance for stakeholders involved in its production and distribution.

The production of Mitomycin's Active Pharmaceutical Ingredient (API) is heavily reliant on Key Starting Materials (KSMs), many of which are sourced from China. China controls approximately 70–80% of the global KSM supply and 60–70% of the global intermediate supply, making it a global leader in this sector. This dependency exposes the supply chain to risks associated with geopolitical tensions, trade disputes, and regulatory changes in China.

In recent years, environmental regulations in China have led to the shutdown of several chemical manufacturing facilities, causing disruptions in the supply of KSMs. For instance, in 2018, the closure of Chinese companies impacted Indian pharmaceutical players due to supply uncertainties emerging out of China, where KSM manufacturers are located. Such events underscore the vulnerability of the Mitomycin supply chain to external factors affecting KSM availability.

The Mitomycin export market from India is highly concentrated, with the top five exporters accounting for 79.5% of total exports. INTAS PHARMACEUTICALS LIMITED and MYLAN LABORATORIES LIMITED each hold a 29.7% share, indicating a significant reliance on a limited number of suppliers. This concentration poses a risk of supply disruptions if any of these key exporters face operational challenges.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at reducing import dependence on critical pharmaceutical ingredients. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G, 6-APA, and Clavulanic Acid, which are crucial for antibiotic production. While this initiative is a positive step, its impact on Mitomycin's supply chain remains to be seen.

Recent geopolitical tensions have significantly impacted global shipping routes. In March 2026, the closure of the Strait of Hormuz following attacks on Iran by the US and Israel disrupted the supply of raw materials to Asia's petrochemical industry, leading to force majeure declarations and production cutbacks. Additionally, the Red Sea and Gulf of Aden have experienced increased threats to commercial shipping, further complicating logistics for pharmaceutical exports.

The US Food and Drug Administration (FDA) has expressed concerns over medical device shortages due to supply chain vulnerabilities, highlighting the broader implications of such disruptions on healthcare. While specific shortage alerts for Mitomycin have not been issued, the interconnected nature of global supply chains suggests a potential risk to its availability.

• Diversify KSM Sourcing: Identify and develop alternative suppliers for KSMs beyond China to reduce dependency and enhance supply chain resilience.

• Strengthen Domestic Production: Invest in domestic manufacturing capabilities for KSMs and APIs to mitigate risks associated with import reliance.

• Enhance Supplier Base: Encourage the entry of additional exporters into the Mitomycin market to reduce concentration and single-source risks.

• Monitor Geopolitical Developments: Establish a proactive monitoring system for geopolitical events that could impact shipping routes and raw material availability.

• Develop Contingency Plans: Create comprehensive contingency plans, including alternative shipping routes and inventory management strategies, to address potential supply chain disruptions.

RISK_LEVEL: MEDIUM